Welcome to the website for the MS in the 21st Century initiative
The MS in the 21st Century initiative began in 2011 with the aim of establishing the principles of high-quality, patient-focused care for the 21st century for people living with Multiple Sclerosis.
A Steering Group of leading international experts involved in MS treatment, management and advocacy was formed to develop a set of overarching principles that would guide the development of MS patient management strategies.
These principles formed the basis of a Consensus Statement that all stakeholders in MS management could endorse.
The Consensus Statement was published in the Journal of Neurology as part of an article authored by the Steering Group, ‘Future MS care: a consensus statement of the MS in the 21st Century Steering Group’, 31st August 2012.
Why is the Consensus
More than 2.5 million people worldwide are estimated to be affected by multiple sclerosis (MS), with almost 500,000 of them living in the European Union (EU).
Current medications slow the accumulation of disability in MS and reduce the frequency of relapses by modulating the body’s immune system. Although scientific evidence exists to show that early access to effective treatment and care is cost-efficient to society and has a meaningful impact on the quality of life of patients, significant disparity still exists between and within countries in the standard of treatment offered to people with MS. There also remains a lack of awareness and education of healthcare professionals, patients and the general public. In addition, available treatments have limited efficacy.
The Steering Group of the MS in the 21st Century initiative believe that it is the right of every patient to have access to early diagnosis, more and better treatment options, rehabilitation and regeneration strategies, and effective management of MS symptoms.
The Steering Group has developed a Consensus Statement that calls upon all regulators, healthcare providers and decision makers, clinicians, industry representatives and patient groups within the MS community to work together to ensure that all people affected by MS have full access to personalised treatment, with reimbursement.